ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "rheumatoid arthritis"

  • Abstract Number: 1654 • ACR Convergence 2021

    Comparative Characteristics of the Natural Course of Early Rheumatoid Arthritis with Onset at a Young Age (18-49 Years) and Older (50 Years and Older) Patients Who Did Not Take DMARDs, Biologics, Other Targeted Drugs, Corticoids According to the Russian Register of Arthritis OREL

    Azamat Satybaldyev, Galina Gridneva, Anna Misiyuk, Natalia Demidova, Kamalia Kasumova and Evgeny Nasonov, V.A. Nasonova Reseach Institute of Rheumatology, Moscow, Russia

    Background/Purpose: Comparison of frequency of different clinical features of the natural course at the stage of early rheumatoid arthritis (RA) in patients with young and…
  • Abstract Number: 1670 • ACR Convergence 2021

    Increased Prevalence of Gastroesophageal Disease Among Patients with Rheumatoid Arthritis: A Systematic Review and Meta-analysis

    Patompong Ungprasert1, Nipith Charoenngam2, Ben Ponvilawan3, Pitchaporn Yingchoncharoen3 and Jerapas Thongpiya4, 1Cleveland Clinic, Cleveland Heights, OH, 2Mount Auburn Hospital, Boston, MA, 3Mahidol University, Bangkok, Thailand, 4Mahdiol University, Bangkok, Thailand

    Background/Purpose: Recent experimental studies have suggested that systemic inflammatory response could lead to impairment of lower esophageal function, resulting in gastroesophageal reflux disease (GERD). Epidemiologic…
  • Abstract Number: 1686 • ACR Convergence 2021

    Efficacy and Safety of Olokizumab in a Phase III Trial of Patients with Moderately to Severely Active Rheumatoid Arthritis Inadequately Controlled by TNF-α Inhibitor Therapy

    Eugen Feist1, Saeed Fatenejad2, Sergey Grishin3, Elena Korneva3, Michael Luggen4, Evgeniy Nasonov5, Mikhail Samsonov6 and Roy Fleischmann7, 1Helios Department of Rheumatology, Vogelsang-Gommern, Germany, 2SFC Medica, LLC, Charlotte, NC, 3R-Pharm, Moscow, Russia, 4Cincinnati Rheumatic Disease Study Group, Inc., and University Hospital/University of Cincinnati College of Medicine, Cincinnati, OH, 5V.A. Nasonova Reseach Institute of Rheumatology, Moscow, Russia, 6RPharm, Moscow, Russia, 7Metroplex Clinical Research Center and University of Texas Southwestern Medical Center, Dallas, TX

    Background/Purpose: Olokizumab (OKZ), a humanized monoclonal antibody targeting IL-6, was studied in patients with active Rheumatoid Arthritis (RA) despite methotrexate (MTX) (NCT02760368, NCT02760407) [1]. Here…
  • Abstract Number: 1702 • ACR Convergence 2021

    Efficacy and Safety of Baricitinib in B/tsDMARDs Naive and B/tsDMARDs-IR Patients with Rheumatoid Arthritis

    MASAOMI YAMASAKI, Shin-Yokohama Arthritis and Rheumatology Clinic, Yokohama, Japan

    Background/Purpose: Baricitinib, an oral selective inhibitor of Janus kinase (JAK) 1 and 2, improved signs and symptoms of rheumatoid arthritis(RA).We analyze efficacy and safety of…
  • Abstract Number: 1912 • ACR Convergence 2021

    Meteorological Variables Have Different Effect on Core Measures of Disease Activity in Patients with Rheumatoid Arthritis

    Peter Mandl1, Paul Studenic2, Farideh Alasti1, Rainer Kaltenberger3, Andreas Kerschbaumer1, Thomas Krennert3, Josef Smolen1 and Daniel Aletaha4, 1Medical University of Vienna, Vienna, Austria, 2Karolinska Institute; & Medical University of Vienna, Stockholm, Sweden, 3Central Institute for Meteorology and Geodynamics, Vienna, Austria, 4Medical University Vienna, Vienna, Austria

    Background/Purpose: The notion that weather conditions may influence the symptoms and course of rheumatic and musculoskeletal diseases goes back to ancient times. We aimed to…
  • Abstract Number: PP11 • ACR Convergence 2021

    “Our Arthritis May Be Chronic but We Are Definitely Iconic” – Two Teens Created a National Podcast for Youth with Rheumatic Diseases

    Trishtha Peters1 and Natasha Trehan2, 1University of Ontario, Toronto, ON, Canada, 2University of Ottawa, Toronto, ON, Canada

    Background/Purpose: Trish Peters was diagnosed with JIA at 11. She has been on Methotrexate to lessen disease activity for her knees and hands. She does…
  • Abstract Number: 0015 • ACR Convergence 2021

    Rheumatoid Factor Recognizes Specific Domains of IgG Heavy Chain Complexed with HLA Class II Molecules

    Shanshan Zhang1, Hideaki Tsuji1, Hui Jin2, Koji Kitagori1, Shuji Akizuki3, Kosaku Murakami1, Ran Nakashima1, Hajime Yoshifuji1, Masao Tanaka1, Hisashi Arase2, Koichiro Ohmura4 and Akio Morinobu1, 1Kyoto University, Kyoto, Japan, 2Osaka University, Osaka, Japan, 3Kyoto Universtiy, Kyoto City, Japan, 4Kobe City Medical Center General Hospital, Kobe, Japan

    Background/Purpose: Rheumatoid factor (RF) is an autoantibody that binds to IgG Fc region (CH2 and CH3 domains) and is detectable in patients with rheumatoid arthritis…
  • Abstract Number: 0033 • ACR Convergence 2021

    Impaired Adipose Tissue Function in Rheumatoid Arthritis: Association with Autoimmunity, Disease Activity and Therapeutic Response

    Iván Arias de la Rosa1, alejandro Escudero2, Cristobal Román-Rodriguez2, Rocio Guzmán-Ruiz2, Maria del Mar Malagón2, Carlos Pérez-Sánchez3, Chamaida Plasencia-Rodríguez4, Ana Martinez-Feito5, Maria del Carmen Ábalos-Aguilera2, Alejandra Patiño-Trives6, Jerusalem Calvo2, Rafaela Ortega2, Eduardo Collantes-Estevez2, Chary Lopez-Pedrera2 and Nuria Barbarroja1, 1University of Cordoba/IMIBIC/Reina Sofia Hospital, Cordoba, Spain, 2IMIBIC/Reina Sofia Hospital/University of Córdoba, Córdoba, Spain, 3IMIBIC, Córdoba, Spain, 4Immuno-Rheumatology Research Group, Hospital La Paz Institute for Health Research-IdiPAZ, Rheumatology, La Paz University Hospital, Madrid, Spain, 5ImmunoRheumatology Department, IDIPAZ, Madrid, Spain, 6Rheumatology Department, Reina Sofia University Hospital/ Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/ University of Cordoba, Cordoba, Spain

    Background/Purpose: 1) to evaluate the relationship among adipose tissue dysfunction, autoimmunity and disease activity in rheumatoid arthritis (RA) patients; 2) to analyze the direct effect…
  • Abstract Number: 0097 • ACR Convergence 2021

    Outcome of SARS-CoV-2 Infection in Patients with Rheumatoid Arthritis Under Treatment with Janus Kinase Inhibitors Compared to Tumour Necrosis Factor Inhibitors

    Rebecca Hasseli1, Bimba Franziska Hoyer2, Hanns-Martin Lorenz3, Alexander Pfeil4, Anne Regierer5, Jutta Richter6, Tim Schmeiser7, Anja Strangfeld8, Reinhard Voll9, Andreas Krause10, Hendrik Schulze-Koops11, Christof Specker12 and Ulf Müller-Ladner13, 1Justus-Liebig-University Giessen, Bad Nauheim, Germany, 2Universittsklinikum Schleswig-Holstein, Kiel, Germany, 3University Hospital Heidelberg Germany, Heidelberg, Germany, 4Friedrich Schiller University Jena, Jena, Germany, 5German Rheumatism Research Center, Berlin, Germany, 6Rheumatology and Hiller Research Unit, Heinrich-Heine-University Duesseldorf, Medical Faculty, Duesseldorf, Germany, 7Private Practice, Cologne, Germany, 8Deutsches Rheuma-Forschungszentrum Berlin, Berlin, Germany, 9Department of Rheumatology and Clinical Immunology, University Medical Center, Faculty of Medicine, Albert-Ludwigs-University of Freiburg, Freiburg, Germany, 10Immanuel Hospital, Berlin, Germany, 11Division of Rheumatology and Clinical Immunology, Department of Internal Medicine IV, University of Munich, Munich, Germany, 12Evangelisches Krankenhaus, Kliniken Essen-Mitte, Essen, Germany, 13JLU Giessen, Campus Kerckhoff, Dept. Rheum & Clin Immunol, Bad Nauheim, Germany

    Background/Purpose: Janus kinase inhibitors (JAK-i) offer a potent mode of action to treat rheumatic diseases. Little is known on the course and outcome of SARS-CoV-2…
  • Abstract Number: 0171 • ACR Convergence 2021

    Bone Erosions and Osteophytes in Premenopausal Women with Long-standing Rheumatoid Arthritis: Association with Systemic Bone Involvement Using HR-pQCT

    Mariana Perez1, Camille Figueiredo1, Lucas Sales1, ANA MEDEIROS-RIBEIRO1, Liliam Takayama1, Diogo Domiciano1, Karina Bonfiglioli1, Valeria Caparbo1 and Rosa Pereira2, 1Rheumatology Division, University of São Paulo, São Paulo, SP, Brazil, 2Rheumatology Division, University of São Paulo, São Paulo, Brazil

    Background/Purpose: Two patterns of bone involvement are described in rheumatoid arthritis (RA), systemic and localized. Systemic bone involvement is characterized by loss of generalized bone…
  • Abstract Number: 0272 • ACR Convergence 2021

    RA Disease Activity Is an Independent Predictor of Left Ventricular Mass Changes in an RA Cohort Without Cardiovascular Disease

    Elizabeth Park1, Kazato Ito1, Christopher Depender1, Jon Giles1 and Joan Bathon2, 1Columbia University Irving Medical Center, Division of Rheumatology, New York, NY, 2Columbia University, New York, NY

    Background/Purpose: Rheumatoid arthritis (RA) patients have 50% increased risk of heart failure (HF) vs non-RA patients with a distinct phenotype, preserved ejection fraction on transthoracic…
  • Abstract Number: 0289 • ACR Convergence 2021

    Developing a Score to Predict Preclinical Interstitial Lung Disease in Patients with Rheumatoid Arthritis – a Cross-Sectional Study from the ESPOIR Cohort

    Pierre Antoine Juge1, Benjamin Granger2, Marie-Pierre Debray3, Esther Ebstein4, Fabienne Louis-sidney5, Joanna Kedra6, Raphaël Borie7, Arnaud Constantin8, Bernard Combe9, Rene-Marc FLIPO10, Xavier Mariette11, Olivier Vittecoq12, Alain Saraux13, Guillermo CARVAJAL-ALEGRIA14, Jean Sibilia15, Francis Berenbaum16, Caroline Kannengiesser17, Catherine Boileau17, Bruno Crestani18, Bruno Fautrel19 and Philippe Dieudé20, 1Hopital Bichat-Claude Bernard, Service de Rhumatologie, Paris, France, 2Département de Santé Publique, Hopital de la Pitié Salpétrière, Paris, France, 3Hopital Bichat, Service de Radiologie, Paris, France, 4Hopital Bichat, Service de Rhumatologie, Paris, 5University Hospital Martinique, Fort de France, Martinique, 6Sorbonne Universit, Institut Pierre Louis d'Epidmiologie et de Sant Publique, Paris, France, 7Hopital Bichat, Service de Pneumologie, Paris, 8Toulouse University Hospital, Toulouse Cedex 9, France, 9CHU Montpellier Montpellier University, Montpellier, France, 10Lille University Hospital, Lille, France, 11Université Paris- Saclay, Rheumatology, Paris, France, 12CHU de Rouen, Service de Rhumatologie, Rouen, France, 13CHU de Brest, Brest Cedex, France, 14CHU de Brest, Service de Rhumatologie, Brest, 15CHU de Strasbourg, Service de Rhumatologie, Strasbourg, France, 16Sorbonne Universit - hopital Saint-Antoine, Paris, France, 17CHU de Bichat, Service de Génétique, Paris, France, 18Hopital Bichat, Paris University, Paris, France, 19Pitié Salpêtrière Hospital, APHP, Sorbonne Université, Paris, France, 20CHU de Bichat, Service de Rhumatologie, Paris, France

    Background/Purpose: Interstitial lung disease (ILD) can be detected in 20% to 60% of patients with rheumatoid arthritis (RA) on high-resolution computed-tomography (HRCT) chest scan and…
  • Abstract Number: 0463 • ACR Convergence 2021

    Treatment Persistence Among Medicare Beneficiaries with Seropositive Rheumatoid Arthritis Initiating Biologic or Targeted Synthetic DMARDs

    Sang Hee Park1, Taylor Schwartz2, Xue Han1, Scott Robinson2, Sumie Kakehi1, Keith Wittstock1, Kris Norris2, Anne Murunga2, Alison Silverstein2 and Jeffrey Sparks3, 1Bristol Myers Squibb, Princeton, NJ, 2Avalere Health, Washington, DC, 3Brigham and Women’s Hospital and Harvard Medical School, Boston, MA

    Background/Purpose: Recent exploratory clinical trial and retrospective studies1 suggest that patients with seropositive RA (rheumatoid factor [RF]+ and/or anti-cyclic citrullinated peptide [anti-CCP]+) treated with abatacept…
  • Abstract Number: 0570 • ACR Convergence 2021

    A Narrowed, but Persistent Mortality Gap: A National, Matched Cohort Study in U.S. Veterans with Rheumatoid Arthritis from 2000-2017

    Tate Johnson1, Yangyuna Yang2, Punyasha Roul2, Brian Sauer3, Joshua Baker4, Ted Mikuls2 and Bryant England2, 1University of Nebraska Medical Center, Elkhorn, NE, 2University of Nebraska Medical Center, Omaha, NE, 3University of Utah, Salt Lake City, UT, 4University of Pennsylvania, Philadelphia, PA

    Background/Purpose: Rheumatoid arthritis (RA) is recognized to increase the risk of premature death. The impact of RA on survival varies across causes of death, though…
  • Abstract Number: 0591 • ACR Convergence 2021

    The Temporal Association Between Hospital Admissions, Disease-modifying Anti-rheumatic Drugs Usage and Direct Health Care Costs in Rheumatoid Arthritis Patients

    Khalid Almutairi1, Johannes Nossent1, David Preen1, Helen Keen2 and Charles Inderjeeth3, 1University of Western Australia, Perth, Australia, 2University of Western Australia, Daglish, Australia, 3University of Western Australia, Nedlands, Perth, Australia

    Background/Purpose: Rheumatoid arthritis (RA) carries a substantial burden for patients and society in terms of morbidity, disability, and medical expenses. The Australian Pharmaceutical Benefits Scheme…
  • « Previous Page
  • 1
  • …
  • 110
  • 111
  • 112
  • 113
  • 114
  • …
  • 188
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology